Skip to content
10-Q

Quarterly Report

NIKA PHARMACEUTICALS, INC NIKA

0001826466-24-000146

← back to feed
Filed
Nov 12, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Nov 11, 2024 1.02B sh
Short Term Debt Q3 2024 · Sep 30, 2024 $210.16K
Short Term Debt Q3 2024 · Dec 31, 2023 $101.75K
Cash And Equivalents Q3 2024 · Sep 30, 2024 $1.39K
Cash And Equivalents Q3 2024 · Dec 31, 2023 $19.6K
Current Liabilities Q3 2024 · Sep 30, 2024 $210.16K
Current Liabilities Q3 2024 · Dec 31, 2023 $101.75K
Total Liabilities Q3 2024 · Sep 30, 2024 $210.16K
Total Liabilities Q3 2024 · Dec 31, 2023 $101.75K
Current Assets Q3 2024 · Sep 30, 2024 $1.39K
Current Assets Q3 2024 · Dec 31, 2023 $19.6K
Total Assets Q3 2024 · Sep 30, 2024 $1.39K
Total Assets Q3 2024 · Dec 31, 2023 $19.6K
Eps Basic Q3 2024 · Sep 30, 2024 $0.00
Eps Basic Q3 2024 · Jun 30, 2024 $0.00
Eps Basic Q3 2024 · Sep 30, 2023 $0.00
Eps Basic Q3 2024 · Jun 30, 2023 $0.00
Shares Diluted Q3 2024 · Jun 30, 2024 1.02B sh
Shares Diluted Q3 2024 · Sep 30, 2023 876.09M sh
Shares Diluted Q3 2024 · Jun 30, 2023 876.09M sh
Eps Diluted Q3 2024 · Jun 30, 2024 $0.00
Eps Diluted Q3 2024 · Sep 30, 2023 $0.00
Eps Diluted Q3 2024 · Jun 30, 2023 $0.00
Sga Expense Q3 2024 · Jun 30, 2024 $6.3K
Sga Expense Q3 2024 · Sep 30, 2023 $57.52K
Sga Expense Q3 2024 · Jun 30, 2023 $10.14K
Net Income Q3 2024 · Jun 30, 2024 −$8.37K
Net Income Q3 2024 · Sep 30, 2023 −$57.52K
Net Income restated Q3 2024 · Jun 30, 2023 −$10.14K
Operating Income Q3 2024 · Jun 30, 2024 −$8.37K
Operating Income Q3 2024 · Sep 30, 2023 −$57.52K
Operating Income Q3 2024 · Jun 30, 2023 −$10.14K
Operating Cash Flow restated Q3 2024 · Sep 30, 2023 −$57.52K
Stockholders Equity Q3 2024 · Sep 30, 2023 −$74.84K
Stockholders Equity Q3 2024 · Jun 30, 2023 −$64.69K
Stockholders Equity Q3 2024 · Mar 31, 2023 −$36.89K
Stockholders Equity Q3 2024 · Dec 31, 2022 −$17.32K